Proteinuria News and Research RSS Feed - Proteinuria News and Research

Proteinuria, also sometimes referred to as albuminuria or urine albumin, is a health condition characterized by an abnormal concentration of protein in the urine.
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Air pollution exposure may have direct role in triggering lupus among children and adolescents

Air pollution exposure may have direct role in triggering lupus among children and adolescents

The results of a study presented today at the European League Against Rheumatism Annual Congress show for the first time that an individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children and adolescents with Systemic Lupus Erythematosus (SLE). [More]
New urine-based diagnostic method may help detect preeclampsia in pregnant women

New urine-based diagnostic method may help detect preeclampsia in pregnant women

A team of scientists from the Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology", Moscow Institute of Physics and Technology, the Emanuel Institute for Biochemical Physics, and the Talrose Institute for Energy Problems of Chemical Physics have developed an approach for a method of non-invasive testing for pregnant women with a serious and complex condition called preeclampsia. [More]
Motor protein Myo1c uses actin cytoskeleton as 'track' for Neph1 transport

Motor protein Myo1c uses actin cytoskeleton as 'track' for Neph1 transport

The motor protein Myo1c binds to Neph1, a protein crucial for ensuring effective filtration by the kidney, and serves as one mode of its cellular transport, according to findings by investigators at the Medical University of South Carolina and their collaborators reported in the May 16, 2016 issue of Molecular and Cellular Biology. [More]
New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

Obstetricians and midwives are today welcoming the publication of new NICE guidance recommending the use of a new test from Roche Diagnostics that can rule-out the development of the life threatening condition, pre-eclampsia, within one week in pregnant women. [More]
Incidence and severity emerging CVD risk factors may differ between genders

Incidence and severity emerging CVD risk factors may differ between genders

The incidence and severity of both traditional and emerging cardiovascular disease (CVD) risk factors as well as the response to treatment may differ between genders. In this narrative review, several emerging CVD risk factors (i.e. inflammatory and haemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease) are discussed in the context of gender differences. [More]
Genetic profiling ‘feasible’ for paediatric cancer patients

Genetic profiling ‘feasible’ for paediatric cancer patients

Research published in JAMA Oncology demonstrates that tumour and germline molecular profiling is feasible in paediatric cancer patients and can have actionable findings. [More]
Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Pre-eclampsia is a serious illness associated with pregnancy, which develops after twenty weeks and is associated with defective ingrowing of the placenta within the mother. The dangerous illness is both the second most frequent cause of death in pregnant women, and the reason for severe complications for mother and child, especially during premature births. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200. [More]
EKF biomarker identifies likely development  of Diabetic Nephropathy

EKF biomarker identifies likely development of Diabetic Nephropathy

EKF Diagnostics, the global in vitro diagnostics company, announces that new data has been presented in support of soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) as a biomarker to predict progression of Diabetic Nephropathy (also referred to as Diabetic Kidney Disease). [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Circulating protein predicts risk of chronic kidney disease

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor. [More]
Preeclampsia during pregnancy linked to heart defects in infants

Preeclampsia during pregnancy linked to heart defects in infants

Pregnant women with preeclampsia have a higher risk of delivering an infant with a congenital heart defect. An extensive study of 1.9 million mother and infant pairs by a team at the University of Montreal Hospital Research Centre has shown significant association between these diseases in mothers and newborns from early pregnancy. [More]
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco. [More]
Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical Limited today announced the first patient had been enrolled in a Phase II study of DMX-200, an innovative new treatment that combines two different drugs to treat chronic kidney disease. [More]
Study finds that serum biomarkers can predict pre-eclampsia risk in pregnant women

Study finds that serum biomarkers can predict pre-eclampsia risk in pregnant women

Levels of biomarkers in the blood of pregnant women can be used to predict which women are at risk of pre-eclampsia, finds a study published today (22 July) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG). ADMA and Hcy, both known to be raised in women with pre-eclampsia, are present in the blood in higher than normal concentrations a month before the onset of the condition. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]
Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
Advertisement